{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:34:00Z","timestamp":1793651640459,"version":"4.5.1"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T00:00:00Z","timestamp":1469059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T00:00:00Z","timestamp":1469059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26929022"],"award-info":[{"award-number":["26929022"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1111\/jcpt.12429","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T09:16:55Z","timestamp":1469092615000},"page":"519-523","source":"Crossref","is-referenced-by-count":27,"title":["Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis"],"prefix":"10.1155","volume":"41","author":[{"given":"W.","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Endocrinology; Huadong Hospital; Fu Dan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Huadong Hospital; Fu Dan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Huashan Hospital; Fu Dan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Huashan Hospital; Fu Dan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Huashan Hospital; Fu Dan University; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,21]]},"reference":[{"key":"10.1111\/jcpt.12429-BIB0001|jcpt12429-cit-0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/01.bor.0000166384.80777.0d","article-title":"Diagnosis and epidemiology of osteoporosis","volume":"17","author":"Dennison","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/jcpt.12429-BIB0002|jcpt12429-cit-0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00223-004-2222-2","article-title":"Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly-a 12-and 22-year follow-up of 257 patients","volume":"76","author":"Hasserius","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"10.1111\/jcpt.12429-BIB0003|jcpt12429-cit-0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Arch Osteoporos"},{"key":"10.1111\/jcpt.12429-BIB0004|jcpt12429-cit-0004","first-page":"1129","article-title":"Meta-analysis on the prevalence rate of osteoporosis in the middle-aged and elderly in China","volume":"18","author":"Han","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1111\/jcpt.12429-BIB0005|jcpt12429-cit-0005","first-page":"9","article-title":"Primary osteoporosis in postmenopausal women","volume":"1","author":"Ji","year":"2015","journal-title":"CDTM"},{"key":"10.1111\/jcpt.12429-BIB0006|jcpt12429-cit-0006","first-page":"2","article-title":"Osteoporosis: epidemiology, diagnosis, and treatment","volume":"93","author":"Iqbal","year":"2000","journal-title":"South Med J"},{"key":"10.1111\/jcpt.12429-BIB0007|jcpt12429-cit-0007","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1111\/jcpt.12429-BIB0008|jcpt12429-cit-0008","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/jcpt.12429-BIB0009|jcpt12429-cit-0009","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12429-BIB0010|jcpt12429-cit-0010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1210\/jc.2008-2241","article-title":"The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women","volume":"94","author":"Grey","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/jcpt.12429-BIB0011|jcpt12429-cit-0011","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12429-BIB0012|jcpt12429-cit-0012","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12429-BIB0013|jcpt12429-cit-0013","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12429-BIB0014|jcpt12429-cit-0014","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1111\/jcpt.12429-BIB0015|jcpt12429-cit-0015","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1111\/jcpt.12429-BIB0016|jcpt12429-cit-0016","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12429-BIB0017|jcpt12429-cit-0017","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","article-title":"A reappraisal of generic bisphosphonates in osteoporosis","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1111\/jcpt.12429-BIB0018|jcpt12429-cit-0018","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15537\/smj.2015.11.12731","article-title":"Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate","volume":"36","author":"Al-Bogami","year":"2015","journal-title":"Saudi Med J"},{"key":"10.1111\/jcpt.12429-BIB0019|jcpt12429-cit-0019","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"key":"10.1111\/jcpt.12429-BIB0020|jcpt12429-cit-0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"key":"10.1111\/jcpt.12429-BIB0021|jcpt12429-cit-0021","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12429-BIB0022|jcpt12429-cit-0022","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s001980050281","article-title":"An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1111\/jcpt.12429-BIB0023|jcpt12429-cit-0023","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2014.01.013","article-title":"Mevalonate metabolism in cancer","volume":"356","author":"Gruenbacher","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1111\/jcpt.12429-BIB0024|jcpt12429-cit-0024","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","article-title":"Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6","volume":"23","author":"Dicuonzo","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"10.1111\/jcpt.12429-BIB0025|jcpt12429-cit-0025","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging"},{"key":"10.1111\/jcpt.12429-BIB0026|jcpt12429-cit-0026","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1111\/jcpt.12429-BIB0027|jcpt12429-cit-0027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1111\/jcpt.12429-BIB0028|jcpt12429-cit-0028","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00774-010-0223-y","article-title":"The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis","volume":"29","author":"Hwang","year":"2011","journal-title":"J Bone Miner Metab"},{"key":"10.1111\/jcpt.12429-BIB0029|jcpt12429-cit-0029","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1111\/jcpt.12429-BIB0030|jcpt12429-cit-0030","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1345\/aph.1G534","article-title":"How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy","volume":"40","author":"Gold","year":"2006","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12429","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12429\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:01:56Z","timestamp":1671818516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,21]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12429","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7,21]]}}}